✨ Free AI Report
Poseida Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Poseida Therapeutics, Inc.
Company Research

Poseida Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics, with a pipeline of autologous and allogeneic chimeric antigen receptor T c...

Analyst-debate audio for Poseida Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Poseida Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

A well-capitalized gene therapy innovator with differentiated allogeneic CAR-T technology, strong pharma partnerships, and clear...

Read the full analyst-debate transcript →
Industry Gene Therapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Poseida Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Poseida Therapeutics, Inc. Overview

Pro stress-test →

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics, with a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates. The company creates CAR-T therapies with high levels of TSCM (stem cell-derived memory T cells) for the treatment of oncological, autoimmune and rare diseases, including multiple myeloma, acute myeloid leukemia and prostate cancer.

Strategic Profile

Pro stress-test →

Poseida's proprietary platforms include the piggyBac non-viral DNA delivery system and the Cas-CLOVER site-specific gene editing system for precise genetic modifications. The company generated $130 million in non-dilutive partnership-related milestones and payments in the first nine months of 2024 and was cash flow positive for that period, with partnerships including Roche and Astellas.

Competitive Landscape

Pro stress-test →

Poseida competes in the allogeneic CAR-T and gene therapy market against players like Juno Therapeutics (Celgene/BMS), Caris Life Sciences, and UniQure. The company differentiates through its non-viral piggyBac DNA delivery platform and Cas-CLOVER gene editing system, enabling off-the-shelf, TSCM-rich CAR-T products. Key competitive advantages include rapid patient accessibility without bridging therapy and favorable tolerability profiles in early clinical data.

Industry Context

Poseida Therapeutics, Inc. operates in Gene Therapy.

Key facts

Founded: 2015 · Headquarters: San Diego, US · Employees: 132 · Revenue: $54.1 million (H1 2024) · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Poseida Therapeutics, Inc..

  • Poseida was acquired by Roche in early 2025.
  • Generated $130 million in partnership milestones and payments through Q3 2024 plus $49 million in R&D reimbursements, achieving cash flow positivity in first nine months of 2024.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2024Q3 2024 financial results show $80 million earned from Roche milestones including P-BCMA-ALLO1 Phase 1b initiation payment and new development candidate nomination
  • September 2024Successful FDA INTERACT meeting for P-FVIII-101 hemophilia A program
  • +2 moreTrack every material event for Poseida Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Poseida Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Juno CAR-TAutologous and allogeneic CAR-T therapies for hematologic malignancies→UniQure Gene TherapyGene therapy for rare genetic disorders→Caris Cell TherapyPrecision oncology and CAR-T cell therapies→

Compare Poseida Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Poseida Therapeutics, Inc. operates in Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Poseida Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Poseida Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Poseida Therapeutics, Inc. do this quarter?”
“Is Poseida Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Poseida Therapeutics, Inc. do?+
Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics, with a pipeline of autologous and allogeneic chimeric antigen receptor T c...
What is Poseida Therapeutics, Inc.'s Cyborg Score?+
Poseida Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Poseida Therapeutics, Inc.'s main competitors?+
Named competitors include Juno CAR-T, UniQure Gene Therapy, Caris Cell Therapy. The full competitive landscape is in the AskCyborg report.
How can I get the full Poseida Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Poseida Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Poseida Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4uniQure N.V.